Titan Pharmaceuticals Announces Initiation of Phase II Non-Small Cell Lung Cancer Study with Ceavac(R) and TriAb(R) by The Radiation Therapy Oncology Group

Study Supported by the National Cancer Institute



Apr 10, 2001, 01:00 ET from Titan Pharmaceuticals, Inc.

    SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ --
 Titan Pharmaceuticals Inc. (Amex:   TTP) today announced initiation of a Phase
 II clinical study of combination therapy with two of its novel monoclonal
 antibodies, CeaVac(R) and TriAb(R), for the treatment of non-small cell lung
 cancer.  The multi-center trial is funded by the National Cancer Institute
 (NCI) and conducted by the Radiation Therapy Oncology Group (RTOG).
     RTOG is a multi-institutional cancer research group funded by the NCI,
 comprised of approximately 250 major clinical centers in the U.S. and Canada,
 with nearly 30 years of experience running clinical trials.  CeaVac and TriAb
 have been selected by the group for evaluation as the first bivalent
 immunotherapy to be evaluated in this patient population.  The study is
 designed to assess the safety and preliminary efficacy of CeaVac and TriAb in
 combination with radiation therapy in patients with stage IIB and stage IIIA
 non-small cell lung cancer.  It will be conducted at multiple centers under
 the direction of Dr. Benjamin Movsas, M.D., at the Fox Chase Cancer Center in
 Philadelphia.
     Commenting on the initiation of this study, Dr. Movsas stated,  "The
 ability of both CeaVac and TriAb to generate robust and sustained anti-cancer
 immune responses has been demonstrated in previous clinical studies.  Based on
 this experience, we are hopeful that this bivalent immunotherapy administered
 in combination with radiation therapy may provide an improved approach to the
 treatment of non-small cell lung cancer."
     CeaVac and TriAb are monoclonal antibodies being developed by Titan as
 potential treatments for several types of cancer.  CeaVac mimics the
 carcinoembryonic antigen (CEA), which is present in a number of tumor types,
 including non-small cell lung cancer, colorectal cancer, pancreatic cancer and
 gastric cancer.  TriAb mimics the human milk fat globule (HMFG) antigen, which
 is present in high density on a number of tumor types, including non-small
 cell lung cancer.  These monoclonal antibodies trigger the immune system's
 response to recognize and attack the targeted cancer cells.  In non-small cell
 lung cancer, tumor cells express both CEA and HMFG.
     "We are pleased that the Radiation Therapy Oncology Group and the National
 Cancer Institute have launched this important clinical trial," said Dr. Louis
 R. Bucalo, Chairman, President and CEO of Titan Pharmaceuticals.  "Titan's
 monoclonal antibody immunotherapeutic products, CeaVac, TriAb and TriGem(TM),
 were developed to be used in combination with current cancer treatments, and
 generate excellent immune responses when used with such standard treatments.
 This study by the RTOG takes advantage of this important property and is
 applying it to the setting of radiation therapy.  Another advantage is that
 these three separate monoclonal products can be used in combination against
 cancers expressing two or more target antigens, providing a simple approach to
 multivalent immunotherapy.  Since many different cancer types express two or
 more of these target antigens, the strategy used in this study can be applied
 to several other types of cancer."
 
     About Titan Pharmaceuticals
     Titan Pharmaceuticals, Inc. (Amex:   TTP) is a biopharmaceutical company
 focused on the development and commercialization of novel treatments for
 central nervous system (CNS) disorders, cancer and other serious and
 life-threatening diseases.  Titan has assembled a deep pipeline of products
 utilizing novel technologies that have the potential to significantly improve
 the treatment of these diseases.  Titan also establishes important
 partnerships with multinational pharmaceutical companies and government
 institutions for the development of its products.  Zomaril(TM), Titan's novel
 drug for the treatment of schizophrenia, is being developed through a
 corporate partnership agreement with Novartis Pharma AG.  Titan has also
 entered into a corporate partnership with Schering AG to develop and
 commercialize Spheramine(R), a novel treatment for Parkinson's disease.  In
 addition, several clinical programs in cancer therapy are supported by large
 oncology cooperative groups that are funded by the National Cancer Institute.
 
     The press release may contain "forward-looking statements" within the
 meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
 Securities Exchange Act of 1934.  Such statements include, but are not limited
 to, any statements relating to the Company's development program and any other
 statements that are not historical facts.  Such statements involve risks and
 uncertainties, including, but not limited to, those risks and uncertainties
 relating to difficulties or delays in development, testing, regulatory
 approval, production and marketing of the Company's drug candidates,
 unexpected adverse side effects or inadequate therapeutic efficacy of the
 Company's drug candidates that could slow or prevent product development or
 commercialization, the uncertainty of patent protection for the Company's
 intellectual property or trade secrets and the Company's ability to obtain
 additional financing if necessary.  Such statements are based on management's
 current expectations, but actual results may differ materially due to various
 factors, including those risks and uncertainties mentioned or referred to in
 this press release.
 
 

SOURCE Titan Pharmaceuticals, Inc.
    SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ --
 Titan Pharmaceuticals Inc. (Amex:   TTP) today announced initiation of a Phase
 II clinical study of combination therapy with two of its novel monoclonal
 antibodies, CeaVac(R) and TriAb(R), for the treatment of non-small cell lung
 cancer.  The multi-center trial is funded by the National Cancer Institute
 (NCI) and conducted by the Radiation Therapy Oncology Group (RTOG).
     RTOG is a multi-institutional cancer research group funded by the NCI,
 comprised of approximately 250 major clinical centers in the U.S. and Canada,
 with nearly 30 years of experience running clinical trials.  CeaVac and TriAb
 have been selected by the group for evaluation as the first bivalent
 immunotherapy to be evaluated in this patient population.  The study is
 designed to assess the safety and preliminary efficacy of CeaVac and TriAb in
 combination with radiation therapy in patients with stage IIB and stage IIIA
 non-small cell lung cancer.  It will be conducted at multiple centers under
 the direction of Dr. Benjamin Movsas, M.D., at the Fox Chase Cancer Center in
 Philadelphia.
     Commenting on the initiation of this study, Dr. Movsas stated,  "The
 ability of both CeaVac and TriAb to generate robust and sustained anti-cancer
 immune responses has been demonstrated in previous clinical studies.  Based on
 this experience, we are hopeful that this bivalent immunotherapy administered
 in combination with radiation therapy may provide an improved approach to the
 treatment of non-small cell lung cancer."
     CeaVac and TriAb are monoclonal antibodies being developed by Titan as
 potential treatments for several types of cancer.  CeaVac mimics the
 carcinoembryonic antigen (CEA), which is present in a number of tumor types,
 including non-small cell lung cancer, colorectal cancer, pancreatic cancer and
 gastric cancer.  TriAb mimics the human milk fat globule (HMFG) antigen, which
 is present in high density on a number of tumor types, including non-small
 cell lung cancer.  These monoclonal antibodies trigger the immune system's
 response to recognize and attack the targeted cancer cells.  In non-small cell
 lung cancer, tumor cells express both CEA and HMFG.
     "We are pleased that the Radiation Therapy Oncology Group and the National
 Cancer Institute have launched this important clinical trial," said Dr. Louis
 R. Bucalo, Chairman, President and CEO of Titan Pharmaceuticals.  "Titan's
 monoclonal antibody immunotherapeutic products, CeaVac, TriAb and TriGem(TM),
 were developed to be used in combination with current cancer treatments, and
 generate excellent immune responses when used with such standard treatments.
 This study by the RTOG takes advantage of this important property and is
 applying it to the setting of radiation therapy.  Another advantage is that
 these three separate monoclonal products can be used in combination against
 cancers expressing two or more target antigens, providing a simple approach to
 multivalent immunotherapy.  Since many different cancer types express two or
 more of these target antigens, the strategy used in this study can be applied
 to several other types of cancer."
 
     About Titan Pharmaceuticals
     Titan Pharmaceuticals, Inc. (Amex:   TTP) is a biopharmaceutical company
 focused on the development and commercialization of novel treatments for
 central nervous system (CNS) disorders, cancer and other serious and
 life-threatening diseases.  Titan has assembled a deep pipeline of products
 utilizing novel technologies that have the potential to significantly improve
 the treatment of these diseases.  Titan also establishes important
 partnerships with multinational pharmaceutical companies and government
 institutions for the development of its products.  Zomaril(TM), Titan's novel
 drug for the treatment of schizophrenia, is being developed through a
 corporate partnership agreement with Novartis Pharma AG.  Titan has also
 entered into a corporate partnership with Schering AG to develop and
 commercialize Spheramine(R), a novel treatment for Parkinson's disease.  In
 addition, several clinical programs in cancer therapy are supported by large
 oncology cooperative groups that are funded by the National Cancer Institute.
 
     The press release may contain "forward-looking statements" within the
 meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
 Securities Exchange Act of 1934.  Such statements include, but are not limited
 to, any statements relating to the Company's development program and any other
 statements that are not historical facts.  Such statements involve risks and
 uncertainties, including, but not limited to, those risks and uncertainties
 relating to difficulties or delays in development, testing, regulatory
 approval, production and marketing of the Company's drug candidates,
 unexpected adverse side effects or inadequate therapeutic efficacy of the
 Company's drug candidates that could slow or prevent product development or
 commercialization, the uncertainty of patent protection for the Company's
 intellectual property or trade secrets and the Company's ability to obtain
 additional financing if necessary.  Such statements are based on management's
 current expectations, but actual results may differ materially due to various
 factors, including those risks and uncertainties mentioned or referred to in
 this press release.
 
 SOURCE  Titan Pharmaceuticals, Inc.